According to Fortune Business Insights, the authorized generics market size was valued at USD 7.85 billion in 2025 and is projected to grow from USD 8.37 billion in 2026 to USD 14.08 billion by 2034, exhibiting a CAGR of 6.71% during the forecast period.

The authorized generics market is witnessing steady growth due to the increasing demand for cost-effective pharmaceutical products, rising healthcare expenditures, and the growing adoption of generic medicines across developed and emerging economies. Authorized generics are marketed under the original New Drug Application (NDA) by brand manufacturers without the brand name, offering affordable treatment options while maintaining the same formulation, safety, and efficacy as branded drugs. The authorized generics market is also benefiting from favorable government initiatives promoting generic drug usage, increasing patent expirations of branded medicines, and expanding healthcare access. Furthermore, pharmaceutical companies are increasingly introducing authorized generics to retain market share after patent exclusivity expires, supporting the long-term expansion of the authorized generics market.

Continue reading for more details:

https://www.fortunebusinessinsights.com/authorized-generics-market-116057

Market Segmentation

The authorized generics market is segmented by product type, therapeutic application, distribution channel, and geography. Based on product type, the market includes oral, injectable, topical, and other dosage forms, with oral formulations accounting for a significant share due to their widespread use in chronic disease treatment. By therapeutic application, the authorized generics market covers cardiovascular diseases, oncology, central nervous system disorders, diabetes, respiratory diseases, infectious diseases, and others, with cardiovascular and diabetes medications representing major revenue contributors because of their high global disease prevalence. Based on distribution channel, the market is divided into hospital pharmacies, retail pharmacies, and online pharmacies, where retail pharmacies continue to dominate due to greater accessibility and higher prescription volumes. Increasing product approvals and expanding generic portfolios continue to strengthen the overall authorized generics market.

Key Players

• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.
• Sandoz Group AG
• Dr. Reddy's Laboratories Ltd.
• Sun Pharmaceutical Industries Ltd.
• Lupin Limited
• Aurobindo Pharma Limited
• Zydus Lifesciences Limited
• Hikma Pharmaceuticals PLC
• Amneal Pharmaceuticals, Inc.

Market Growth

The authorized generics market is experiencing consistent growth due to increasing efforts to reduce healthcare costs and improve patient access to affordable medicines. The market is expected to expand from USD 8.37 billion in 2026 to USD 14.08 billion by 2034, supported by a CAGR of 6.71%. Rising patent expirations of blockbuster drugs are creating significant opportunities for manufacturers to introduce authorized generics, enabling brand owners to retain revenue while offering lower-priced alternatives. Growing awareness among patients regarding affordable treatment options, supportive regulatory frameworks encouraging generic substitution, and the increasing burden of chronic diseases are further driving the authorized generics market. Strategic collaborations, licensing agreements, and product portfolio expansions by leading pharmaceutical companies are also contributing to sustained market growth.

Restraining Factors

Despite favorable growth prospects, the authorized generics market faces several challenges. Intense competition from independent generic manufacturers often limits pricing flexibility and profit margins for authorized generic products. Regulatory complexities associated with drug approvals and compliance requirements across different countries can delay product launches. Patent litigation, evolving reimbursement policies, and pricing pressures from healthcare providers and government agencies also restrain the expansion of the authorized generics market. Additionally, supply chain disruptions and manufacturing challenges may impact product availability, while increasing competition from biosimilars and alternative therapies could affect market growth in certain therapeutic segments.

Regional Analysis

North America dominated the authorized generics market with a 41.78% market share in 2025, driven by a well-established pharmaceutical industry, high generic drug adoption, supportive regulatory policies, and the presence of leading pharmaceutical manufacturers. The United States remains the largest contributor due to its large patient population, favorable reimbursement environment, and increasing focus on reducing prescription drug costs. Europe represents another significant region in the authorized generics market, supported by government initiatives promoting generic medicines, rising healthcare spending, and strong pharmaceutical manufacturing capabilities. Asia Pacific is expected to witness the fastest growth during the forecast period owing to expanding healthcare infrastructure, increasing access to affordable medicines, growing pharmaceutical production, and rising awareness regarding generic therapies in countries such as China, India, and Japan. Latin America and the Middle East & Africa are also expected to experience steady growth as healthcare access improves and demand for cost-effective medications continues to rise.